DiaMedica Therapeutics Inc (DMAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $474.29M
Last updated: Nov 17, 2026 at 11:03 AM ET
DiaMedica Therapeutics Inc (DMAC) Competitors
The companies most similar to DiaMedica Therapeutics are CorMedix (CRMD), MiMedx Group (MDXG) and Design Therapeutics (DSGN). By market cap, DiaMedica Therapeutics ranks 6th of the 13 companies on this page; DBV Technologies (DBVT) is the largest at $692.19M.
Peer Comparison
DMAC's revenue growth of 0.0% is above the peer median of -21.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics (DMAC) | $474.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| MiMedx Group Inc (MDXG) | $468.42M | 106.0x | 1.5x | -6.3% | N/A | -45.2% | 0.00% |
| Design Therapeutics Inc (DSGN) | $670.46M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Prothena Corporation plc (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| 4D Molecular Therapeutics Inc (FDMT) | $689.52M | N/A | 8.5x | -208.6% | -46.4% | 4506.0% | 0.00% |
| Editas Medicine Inc (EDIT) | $334.92M | N/A | 5.6x | -145.0% | -42.3% | 37.4% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Peer median | $470.99M | 56.2x | 5.6x | 0.0% | -42.3% | -21.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to DiaMedica Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
| MiMedx Group Inc (MDXG) | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia. | MDXG competitors |
| Design Therapeutics Inc (DSGN) | Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. | DSGN competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Prothena Corporation plc (PRTA) | Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases... | PRTA competitors |
| 4D Molecular Therapeutics Inc (FDMT) | 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. | FDMT competitors |
| Editas Medicine Inc (EDIT) | Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. | EDIT competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
Frequently Asked Questions About DMAC
Who are DiaMedica Therapeutics' main competitors?
The companies most similar to DiaMedica Therapeutics include CorMedix (CRMD), MiMedx Group (MDXG), Design Therapeutics (DSGN), Phathom Pharmaceuticals (PHAT) and Prothena Corporation (PRTA), listed from the closest match.
Who is DiaMedica Therapeutics' biggest competitor?
DBV Technologies (DBVT) is the largest of the similar companies at $692.19M; CorMedix (CRMD) is the closest match by business profile, size, sector and industry.
How does DMAC stock compare with its competitors?
DMAC's net margin is 0.0% against a peer median of 0.0%.
Which of DiaMedica Therapeutics' competitors pays a higher dividend?
DiaMedica Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is DiaMedica Therapeutics bigger than its competitors?
No. DiaMedica Therapeutics is 6th by market cap among the 13 companies on this page; the largest is DBV Technologies (DBVT) at $692.19M.
DMAC pages: Overview, Earnings, Forecast, Financials, Competitors